⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TCRX News
TScan Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
TCRX
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care
prnewswire.com
DAWN
TCRX
ENGN
ONCY
GILD
Form 8-K
sec.gov
TCRX
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
globenewswire.com
TCRX
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
globenewswire.com
TCRX
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
globenewswire.com
TCRX
Off-Site Prefabricated Building Industry Research Report 2026: $169.7 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
globenewswire.com
TCRX
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
prnewswire.com
GTBP
ADCT
STRO
CRNX
TCRX
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
globenewswire.com
TCRX
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
prnewswire.com
GTBP
GERN
KURA
SLS
TCRX